open access
Vol 48, No 3 (2010)
Original paper
Submitted: 2011-12-19
Published online: 2010-11-13
Get Citation
Biomarkers as prognostic factors in endometrial cancer.
,
DOI: 10.2478/v10042-10-0061-8
·
Folia Histochem Cytobiol 2010;48(3):319-322.
open access
Vol 48, No 3 (2010)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2010-11-13
Abstract
Endometrial cancer is the most common gynecologic malignancy in more developed countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis and endometrioid histology and type II, associated with a poor prognosis and non-endometrioid histology. This review will focus primarily on the molecular biomarkers that have supported the dualistic model of endometrial carcinoma and help determine which patients would benefit from either adjuvant therapy or more aggressive primary treatment.
Abstract
Endometrial cancer is the most common gynecologic malignancy in more developed countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis and endometrioid histology and type II, associated with a poor prognosis and non-endometrioid histology. This review will focus primarily on the molecular biomarkers that have supported the dualistic model of endometrial carcinoma and help determine which patients would benefit from either adjuvant therapy or more aggressive primary treatment.
Get Citation
About this articleTitle
Biomarkers as prognostic factors in endometrial cancer.
Journal
Folia Histochemica et Cytobiologica
Issue
Article type
Original paper
Pages
319-322
Published online
2010-11-13
Page views
2590
Article views/downloads
2511
DOI
10.2478/v10042-10-0061-8
Bibliographic record
Folia Histochem Cytobiol 2010;48(3):319-322.
Authors
Bożena Dobrzycka
Sławomir J Terlikowski
